Rigel Pharmaceuticals, Inc. (“Rigel”) (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel’s Board of Directors and granted as an inducement material to an employee’s entering into employment.
| SOUTH SAN FRANCISCO, Calif., Dec. 9, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (“Rigel”) (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel’s Board of Directors and granted as an inducement material to an employee’s entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 187,500 stock options to Ray Furey vesting over four years with a one-year cliff. Additionally, Mr. Furey was granted 187,500 stock options to vest upon achievement of certain future performance conditions, subject to Mr. Furey’s continuous service to the Company on such vesting date. Rigel is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4). About Rigel Rigel Contacts Investors:
SOURCE Rigel Pharmaceuticals, Inc. | ||
Company Codes: NASDAQ-NMS:RIGL |
View original content to download multimedia:
